Cited by 306Cannabis and Cannabinoid ResearchMedicinal Plant Extracts EffectsPsychedelics and Drug Studies

The DOI matches its Crossref record; 211 of the 213 references it cites were found in a registry or an index.

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Open access

García-Gutiérrez, María S., Navarrete, Francisco, Gasparyan, Ani, Austrich-Olivares, Amaya, Sala, Francisco, Manzanares, Jorge·2020·Biomolecules

DOI 10.3390/biom10111575PMC PMC7699613

Open this paper in CoChat — free account Open PDF

Abstract

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/biom10111575

Cites

211 of 211 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Schematic representation of the main hypothesized mechanisms described for the anxiolytic, antidepressant and antipsychotic actions of CBD. AEA: anandamide; 5-HT1A: serotonin receptor 1A; BDNF: brain delivered neurotrophic factor; CB1r: cannabinoid CB1 receptor; CB2r: cannabinoid CB2 receptor; ChAT: choline acetyltransferase; D2: dopamine receptor D2; DNA methyl: DNA methylation; ECS: endocannabinoid system; FAAH: fatty acid amide hydrolase; HPA axis: hypothalamus pituitary-axis; M1/M4r: muscarinic receptor 1 and 4; PPARγ: peroxisome proliferator activated receptor gamma; TRKb/mTOR: tropomyosin-receptor-kinase B/mammalian target of rapamycin; TRPV1: transient receptor potential cation channel subfamily V member 1.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
Psychological autopsy studies of suicide: a systematic review.
CAVANAGH, J. T. O., CARSON, A. J., SHARPE, M., & LAWRIE, S. M. (2003) · Psychological Medicine · doi:10.1017/s0033291702006943 · Cited by 2,207
The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Schizophrenia as a Disorder of Neurodevelopment
Lewis, D. A., & Levitt, P. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142754 · Cited by 1,163
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059

Show all 213 references

Research works printed but not linked: 5

Patel, V., Laxminarayan, R., Medina-Mora, M.L., Dua, T., and Chisholm, D. (2016). Chapter 2 Global burden of mental, neurological and substance use disorder: An analysis from the global burden of disease study 2010. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, The International Bank for Reconstruction and Development. [3rd ed.].
Hawksworth, G.M.K. (2004). Metabolism and Pharmacokinetics of Cannabinoids, Pharmaceutical Press.
Sylantyev, S.J.T., Ross, R.A., and Rusakov, D.A. (2011, January 12–16). The enigmatic receptor GPR55 potentiates neurotransmitter release at central synapses. Proceedings of the Neuroscience Meeting Planner Washington, DC: Society for Neuroscience Online: Program, Washington, DC, USA. Program 653.01, Poster B28.
Heather, A., Church, A.C., and Lucey, J.V. (2012). Core Psychiatry, Elsevier. [3rd ed.].
Aragones, 2009, Comorbidity of major depression with other common mental disorders in primary care patients, Aten Primaria, 41, 545

Sorted by citations

Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01519-z · Cited by 246
“394 CBD ’ s therapeutic potential for reducing depression-like behavior has been shown, since it interacts with a wide range of brain molecules 395,396 .”
Background
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
Stella, B., Baratta, F., Pepa, C. D., Arpicco, S., Gastaldi, D., & Dosio, F. (2021) · Drugs · doi:10.1007/s40265-021-01579-x · Cited by 181
Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities
Grifoni, L., Vanti, G., Donato, R., Sacco, C., & Bilia, A. R. (2022) · Molecules · doi:10.3390/molecules27186070 · Cited by 118
Latest updates on the serotonergic system in depression and anxiety
Lin, J., Liu, W., Guan, J., Cui, J.-N., Shi, R.-L., Wang, L., Chen, D., & Liu, Y. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1124112 · Cited by 88
Citrus limon L. (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration
Rahman, M. M., Islam, F., Parvez, A., Azad, A., Ashraf, G. M., Ullah, M. F., & Ahmed, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2101042 · Cited by 76
Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression
Zádor, F., Joca, S. R. L., Nagy-Grócz, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Benyhe, S., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115903 · Cited by 76
An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects
Naya, N. M., Kelly, J., Corna, G., Golino, M., Polizio, A. H., Abbate, A., Toldo, S. A., & Mezzaroma, E. (2024) · Molecules · doi:10.3390/molecules29020473 · Cited by 83
Delivering therapeutic cannabinoids via skin: Current state and future perspectives
Tijani, A. O., Thakur, D., Mishra, D., Frempong, D., Chukwunyere, U. I., & Puri, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.005 · Cited by 68
Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions
Tadijan, A., Vlašić, I., Vlainić, J., Đikić, D., Oršolić, N., & Jembrek, M. J. (2022) · Antioxidants · doi:10.3390/antiox11102049 · Cited by 68
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review
Singh, K., Bhushan, B., Chanchal, D. K., Sharma, S. K., Rani, K., Yadav, M. K., Porwal, P., Kumar, S., Sharma, A., Virmani, T., et al. (2023) · Behavioural Neurology · doi:10.1155/2023/8825358 · Cited by 76
Neuropharmacological and Antidiabetic Potential of Lannea coromandelica (Houtt.) Merr. Leaves Extract: An Experimental Analysis
Islam, F., Mitra, S., Nafady, M. H., Rahman, M. T., Tirth, V., Akter, A., Emran, T. B., Mohamed, A. A.-R., Algahtani, A., & El-Kholy, S. S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6144733 · Cited by 70
Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study
Devinsky, O., Kraft, K. S., Rusch, L. M., Fein, M., & Leone‐Bay, A. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.012 · Cited by 64
Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment
Campos, R. M. P., Aguiar, A. F. L., Paes-Colli, Y., Trindade, P. M. P., Ferreira, B. K., Reis, R. A. D. M., & Sampaio, L. D. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.785176 · Cited by 59
The therapeutic potential of purified cannabidiol
O’Sullivan, S. E., Jensen, S. S., Nikolajsen, G. N., Bruun, H. Z., Bhuller, R., & Hoeng, J. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00186-9 · Cited by 61
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Richardson, B., MacPherson, A., & Bambico, F. R. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100554 · Cited by 57
Neuropharmacological Effects of Terpenoids on Preclinical Animal Models of Psychiatric Disorders: A Review
Mony, T. J., Elahi, F., Choi, J. W., & Park, S. J. (2022) · Antioxidants · doi:10.3390/antiox11091834 · Cited by 58
Down and High: Reflections Regarding Depression and Cannabis
Langlois, C. C., Potvin, S., Khullar, A., & Tourjman, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.625158 · Cited by 51
Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry
Rifkin-Zybutz, R. P., Erridge, S., Holvey, C., Coomber, R., Gaffney, J., Lawn, W., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06399-3 · Cited by 53
An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives
Wang, X., Zhang, H., Liu, Y., Yang, X., Yang, B., Li, H., & Chen, L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106810 · Cited by 57
Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice
Austrich-Olivares, A., García‐Gutiérrez, M. S., Illescas, L., Gasparyan, A., & Manzanares, J. (2022) · Pharmaceuticals · doi:10.3390/ph15040473 · Cited by 52
Self-citation
A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress
Constable, P. A., Al-Dasooqi, D., Bruce, R., & Senthil, M. P. (2022) · Clinical Optometry · doi:10.2147/opto.s355091 · Cited by 48
Citalopram and Cannabidiol
Anderson, L. L., Doohan, P. T., Oldfield, L., Kevin, R. C., Arnold, J. C., Berger, M., Amminger, G. P., & McGregor, I. S. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001427 · Cited by 48
Selected Seeds as Sources of Bioactive Compounds with Diverse Biological Activities
Sławińska, N., & Olas, B. (2022) · Nutrients · doi:10.3390/nu15010187 · Cited by 54
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Yau, G. T. Y., Tai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03469-1 · Cited by 48
Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
Morcuende, Á., García‐Gutiérrez, M. S., Tambaro, S., Nieto, E. O., Manzanares, J., & Femenía, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.866052 · Cited by 45
Self-citation
Miswiring the brain: Human prenatal Δ9-tetrahydrocannabinol use associated with altered fetal hippocampal brain network connectivity
Thomason, M. E., Palopoli, A. C., Jariwala, N. N., Werchan, D. M., Chen, A., Adhikari, S., Espinoza‐Heredia, C., Brito, N. H., & Trentacosta, C. J. (2021) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2021.101000 · Cited by 43
Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence
Bright, U., & Akirav, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105526 · Cited by 48
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze
Fabris, D., de Carvalho, M. C., Brandão, M. L., Prado, W. A., Zuardi, A. W., Crippa, J. A. S., de Oliveira, A. R., Lovick, T. A., & Genaro, K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221125440 · Cited by 43
THC, CBD, and Anxiety: a Review of Recent Findings on the Anxiolytic and Anxiogenic Effects of Cannabis’ Primary Cannabinoids
Lichenstein, S. D. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00450-7 · Cited by 38
Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations
Aziz, A.-I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Mkaddem, S. B. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0133 · Cited by 41
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Štark, T., Martino, S. D., Drago, F., Wotjak, C. T., & Micale, V. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105938 · Cited by 37
Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects
Álvarez-Mon, M. Á., Ortega, M. A., Montero, C. G., Fraile‐Μartinez, O., Monserrat, J., Lahera, G., Mora, F., Rodríguez-Quiroga, A., Fernández-Rojo, S., Quintero, J., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080821 · Cited by 38
Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review
Matheson, J., Bourgault, Z., & Foll, B. L. (2022) · Biomolecules · doi:10.3390/biom12101462 · Cited by 37
Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection
Janecki, M., Graczyk, M., Lewandowska, A. A., & Pawlak, Ł. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084170 · Cited by 33
Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective
Ledesma‐Corvi, S., Hernández‐Hernández, E., & García-Fuster, M. J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01994-y · Cited by 33
Development of Stimuli-Responsive Chitosan/ZnO NPs Transdermal Systems for Controlled Cannabidiol Delivery
Radwan-Pragłowska, J., Janus, Ł., Piątkowski, M., Sierakowska, A., Szajna, E., Matýsek, D., & Bogdał, D. (2021) · Polymers · doi:10.3390/polym13020211 · Cited by 31
Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia
Saleem, A., Qurat-ul-Ain, Q.-U.-A., & Akhtar, M. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.895668 · Cited by 34
Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies
Gasparyan, A., Navarro, D., Navarrete, F., & Manzanares, J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109211 · Cited by 34
Self-citation
Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits
Jha, S. K., Nelson, V. K., Suryadevara, P. R., Panda, S. P., Pullaiah, C. P., Nuli, M. V., Kamal, M., Imran, M., Ausali, S., Abomughaid, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102386 · Cited by 32
CBD-Loaded Nanostructured Lipid Carriers: Optimization, Characterization, and Stability
Xie, Y., Li, P., Fu, D., Yang, F., Sui, X., Huang, B., Liu, J., & Chi, J. (2024) · ACS Omega · doi:10.1021/acsomega.4c04771 · Cited by 29
Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial
Hermush, V., Ore, L., Stern, N., Mizrahi, N., Fried, M., Krivoshey, M., Staghon, E., Lederman, V. E., & Schleider, L. B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.951889 · Cited by 33
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial
Gundugurti, P. R., Banda, N., Yadlapalli, S. S. R., Narala, A., Thatikonda, R., Kocherlakota, C., & Kothapalli, K. S. D. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104073 · Cited by 27
Acute objective and subjective intoxication effects of legal-market high potency THC-dominant versus CBD-dominant cannabis concentrates
Drennan, M. L., Karoly, H. C., Bryan, A. D., Hutchison, K. E., & Bidwell, L. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-01128-2 · Cited by 27
Medicinal Cannabis and Central Nervous System Disorders
Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 29
Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
Palumbo, J., Thomas, B. F., Budimirovic, D. B., Siegel, S. J., Tassone, F., Hagerman, R. J., Faulk, C. D., O’Quinn, S., & Sebree, T. B. (2023) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-023-09475-z · Cited by 28
Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review
Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 33
Differences in the Perception of Dietary Supplements between Dietary Supplement/Medicine Users and Non-Users
Chiba, T., & Tanemura, N. (2022) · Nutrients · doi:10.3390/nu14194114 · Cited by 29
Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study
Bidwell, L. C., Martin‐Willett, R., Skrzynski, C. J., Lisano, J. K., Torres, M. O., Giordano, G., Hutchison, K. E., & Bryan, A. D. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0187 · Cited by 26
Investigation of Potential Antioxidant, Thrombolytic and Neuropharmacological Activities of Homalomena aromatica Leaves Using Experimental and In Silico Approaches
Ali, M. S., Sayem, S. A. J., Habibullah, Quah, Y., Lee, E., Birhanu, B. T., Suk, K., & Park, S. (2021) · Molecules · doi:10.3390/molecules26040975 · Cited by 28
Cannabidiol and Beta-Caryophyllene in Combination: A Therapeutic Functional Interaction
Blanton, H. L., Yin, L., Duong, J., & Benamar, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415470 · Cited by 26
Cannabidiol Intervention for Muscular Tension, Pain, and Sleep Bruxism Intensity—A Randomized, Double-Blind Clinical Trial
Walczyńska-Dragon, K., Kurek-Górecka, A., Niemczyk, W., Nowak, Z., Baron, S., Olczyk, P., Nitecka-Buchta, A., & Kempa, W. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051417 · Cited by 31
Health Benefits of Functional Foods
Jurek, J. M. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1598 · Cited by 31
Tryptophan metabolism in health and disease- implications for non-communicable diseases
Gabela, A. M., Mthembu, N., & Hadebe, S. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107093 · Cited by 31
Cannabinoids and sleep-wake cycle: The potential role of serotonin
Vaseghi, S., Arjmandi-Rad, S., Nasehi, M., & Zarrindast, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113440 · Cited by 24
Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity
Kisiolek, J. N., Flores, V. A., Ramani, A. H., Butler, B., Haughian, J. M., & Stewart, L. K. (2023) · Nutrients · doi:10.3390/nu15194173 · Cited by 25
Development of cannabidiol derivatives as potent broad-spectrum antibacterial agents with membrane-disruptive mechanism
Fang, S., Kang, W.-T., Li, H., Cai, Q., Liang, W., Zeng, M., Yu, Q., Zhong, R., Tao, Y., Liu, S., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116149 · Cited by 24
Novel rapid treatment options for adolescent depression
Ledesma‐Corvi, S., Jornet-Plaza, J., Gálvez‐Melero, L., & García-Fuster, M. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107085 · Cited by 22
Peculiarities of meroterpenoids and their bioproduction
Han, J., Jiang, L., Zhang, L., Quinn, R. J., Liu, X., & Feng, Y. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11312-z · Cited by 23
Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice
Han, X., Song, X., Song, D., Xie, G., Guo, H., Wu, N., & Li, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06132-6 · Cited by 26
CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity
Castelli, V., Lavanco, G., D’Amico, C., Feo, S., Tringali, G., Kuchař, M., Cannizzaro, C., & Brancato, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1237485 · Cited by 23
Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims
Engeli, B. E., Lachenmeier, D. W., Diel, P. R., Guth, S., Villar-Fernandez, M., Roth, A., Lampen, A., Cartus, A. T., Wätjen, W., Hengstler, J. G., et al. (2025) · Nutrients · doi:10.3390/nu17030489 · Cited by 23
Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 23
The Use of Cannabidiol as a Novel Treatment for Oral Stereotypic Behaviour (Crib-Biting) in a Horse
Cunha, R. Z., Felisardo, L. L., Salamanca, G., Marchioni, G. G., Neto, O. I., & Chiocchetti, R. (2022) · Veterinary and Animal Science · doi:10.1016/j.vas.2023.100289 · Cited by 22
Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists
Więckiewicz, G., Stokłosa, I., Stokłosa, M., Gorczyca, P. W., & Pudło, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.837946 · Cited by 21
Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration
Schwotzer, D., Kulpa, J., Trexler, K. R., Dye, W. W., Jantzi, J., Irshad, H., Ware, M. A., Bonn‐Miller, M. O., McDonald, J. D., & Lefever, T. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0121 · Cited by 21
Antidepressant-like effects of cannabidiol in a rat model of early-life stress with or without adolescent cocaine exposure
Bis‐Humbert, C., García‐Cabrerizo, R., & García-Fuster, M. J. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00285-5 · Cited by 20
Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol
Kudrich, C., Hurd, Y. L., Salsitz, E. A., & Wang, A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0089 · Cited by 21
The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol
dos Santos, A. H., Vila-Verde, C., Guimarães, F. S., Joca, S. R. L., & Lisboa, S. F. D. S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411101217 · Cited by 20
Shared genetic architecture highlights the bidirectional association between major depressive disorder and fracture risk
Zhao, P., Ying, Z., Yuan, C., Zhang, H., Dong, A., Tao, J., Yi, X., Yang, M., Jin, W., Tian, W., et al. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101418 · Cited by 19
Cannabidiol–loaded biomimetic macrophage membrane vesicles against post–traumatic stress disorder assisted by ultrasound
Li, Q., Wang, C., Hu, J., Jiao, W., Tang, Z., Song, X., Wu, Y., Dai, J., Gao, P., Du, L., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122872 · Cited by 19
Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders
Coelho, A. A., Bastos, S., Gobira, P. H., & Lisboa, S. F. D. S. (2023) · Neuronal Signaling · doi:10.1042/ns20220034 · Cited by 22
Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 23-Factorial Design
Vlad, R.-A., Antonoaea, P., Todoran, N., RÉDAI, E. M., Bîrsan, M., Muntean, D.-L., Imre, S., Hancu, G., Farczádi, L., & Ciurba, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071467 · Cited by 22
Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence
Zavala‐Tecuapetla, C., Luna‐Munguía, H., López‐Meraz, M. L., & Cuéllar‐Herrera, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416181 · Cited by 19
Analysis of influencing factors of anxiety and depression in maintenance hemodialysis patients and its correlation with BDNF, NT-3 and 5-HT levels
Peng, X., Feng, S.-J., Zhang, P., Sang, S., & Zhang, Y. (2023) · PeerJ · doi:10.7717/peerj.16068 · Cited by 17
A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance
Murphy, M., Erridge, S., Holvey, C., Coomber, R., Rucker, J., & Sodergren, M. H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12407 · Cited by 17
Cannabidiol and Other Cannabinoids in Demyelinating Diseases
Navarrete, C. M., García‐Martín, A., Rolland, A. P., DeMesa, J., & Muñóz, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062992 · Cited by 20
Vitiligo and Mental Health: Natural Compounds’ Usefulness
Bartolomeo, L. D., Custurone, P., Irrera, N., Borgia, F., Vaccaro, F., Squadrito, F., & Vaccaro, M. (2023) · Antioxidants · doi:10.3390/antiox12010176 · Cited by 18
Cannabidiol protects the liver from α-Amanitin-induced apoptosis and oxidative stress through the regulation of Nrf2
Wang, H., Yang, G., Zhang, X., Zhang, H., Liu, Y., Wang, C., Miao, L., Li, Y., Huang, Y., Teng, H., et al. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114196 · Cited by 17
Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases
Naya, N. M., Kelly, J., Hogwood, A. C., Abbate, A., & Toldo, S. A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2351513 · Cited by 20
Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats
Hernández‐Hernández, E., & García-Fuster, M. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891842 · Cited by 16
Cannabidiol—A friend or a foe?
Tihăuan, B.-M., Onisei, T., Slootweg, W., Gună, D., Iliescu, C., & Chifiriuc, M. C. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107036 · Cited by 16
ESTUDO ANATOMOPATOLÓGICO DO IMPACTO DAS LESÕES CAUSADAS PELA Dirofilaria immitis EM FELINOS: UMA REVISÃO DE LITERATURA
de Oliveira, L. C., Holanda, M. M. V., Santos, M., Teles, A. V. D. A., Farias, T. C., Rodrigues, K. C., de Almeida, M. C., Filgueiras, J. R. S. R., Rocha, G. D. S., Silva, F. M. D. O. E., et al. (2025) · Editora In Vivo eBooks · doi:10.47242/978-65-87959-74-0-9 · Cited by 14
TRATAMENTO CIRÚRGICO E ADJUVANTE DAS NEOPLASIAS MAMÁRIAS EM CADELAS
Pinheiro, G. C., Felix, J. P. D. S., de Pina, S. S., Amaral, L. I. R., Almeida, M. E. D. R., Filgueiras, J. R. S. R., Trindade, L. C. B., de Castro, K. K. R., Rocha, G. D. S., Esteves, M. J. B., et al. (2025) · Editora In Vivo eBooks · doi:10.47242/978-65-87959-74-0-12 · Cited by 14
DIABETES MELLITUS EM CÃES: UMA ABORDAGEM TERAPÊUTICA
do Amaral, C. C., Passos, E. G., Guedes, R. F. D. M., Silva, F. M. D. O. E., Bezerra, B. M. O., Cortez, A. A., Chaves, R. N., Santos, B. M. B., Rondon, F. C. M., & Cruz, C. E. B. (2025) · Editora In Vivo eBooks · doi:10.47242/978-65-87959-74-0-14 · Cited by 14
Zebrafish as an Animal Model in Cannabinoid Research
Lachowicz, J. I., Szopa, A., Ignatiuk, K., Świąder, K., & Serefko, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310455 · Cited by 15
How “K-Style” has influenced the younger generation through local Vietnamese influencers
Kim, H., & Choo, H. J. (2023) · Fashion and Textiles · doi:10.1186/s40691-023-00359-3 · Cited by 20
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review
Cammà, G., Verdouw, M. P., van der Meer, P. B., Groenink, L., & Batalla, A. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.10.006 · Cited by 16
Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain
Tito, P. A. L., Bernardino, T. C. D. S., Bellozi, P. M. Q., da Silva, M. C. M., de Miranda, A. S., Vieira, É. L. M., Moreira, F. A., Palotás, A., de Oliveira, A. C. P., & Reis, H. J. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00301-8 · Cited by 15
Cannabis consumption and prosociality
Vigil, J. M., Stith, S. S., & Chanel, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-12202-8 · Cited by 17
A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells
Yu, L., Madsen, F. B., Eriksen, S. H., Andersen, A. J. C., & Skov, A. L. (2022) · Phytochemical Analysis · doi:10.1002/pca.3188 · Cited by 15
Spinal glia-driven neuroinflammation as a therapeutic target for neuropathic pain: Rational development of novel analgesics
Zhang, Z., Niu, Z., & Dong, S. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106404 · Cited by 18
The effects of cannabidiol and Δ9-tetrahydrocannabinol, alone and in combination, in the maximal electroshock seizure model
Dlugosz, L., Zhou, H. Z., Scott, B. W., & Burnham, W. M. (2023) · Epilepsy Research · doi:10.1016/j.eplepsyres.2023.107087 · Cited by 17
Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies
Provenzano, R., Caro, C. D., Vitiello, A., Izzo, L., Ritieni, A., Ungaro, F., Quaglia, F., Russo, E., Miro, A., & d’Angelo, I. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01481-x · Cited by 15
An In Silico Study for Expanding the Utility of Cannabidiol in Alzheimer’s Disease Therapeutic Development
Choi, K., Lee, Y., & Kim, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242116013 · Cited by 13
Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells
Kwon, I.-S., Hwang, Y.-N., Park, J., Na, H.-H., Kwon, T.-H., Park, J.-S., & Kim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316621 · Cited by 13
Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality
Carrascosa, A. J., Navarrete, F., Saldaña, R., García‐Gutiérrez, M. S., Moreno, B. M., Navarro, D., Gómez-Guijarro, F. M., Gasparyan, A., Murcia-Sánchez, E., Torregrosa, A. B., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116268 · Cited by 16
Self-citation
Cannabidiol alters psychophysiological, craving and anxiety responses in an alcohol cue reactivity task: A cross‐over randomized controlled trial
Hurzeler, T. P., Logge, W., Watt, J., McGregor, I. S., Suraev, A. S., Haber, P., & Morley, K. C. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15514 · Cited by 13
Molecular Basis of Anxiety: A Comprehensive Review of 2014–2024 Clinical and Preclinical Studies
Merkouris, E., Brasinika, A., Patsiavoura, M., Siniosoglou, C., Tsiptsios, D., Triantafyllis, A. S., Mueller, C., Mpikou, I., Samara, M. T., Christodoulou, G. N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115417 · Cited by 13
Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model
García‐Gutiérrez, M. S., Navarro, D., Austrich-Olivares, A., & Manzanares, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1171646 · Cited by 12
Self-citation
The two synthetic cannabinoid compounds 4′‐ F‐CBD and HU ‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes
Pereira, M. D. S., Santos, B. M., Giménez, R., Guimarães, F. S., Raisman‐Vozari, R., Bel, E. A. D., & Michel, P. P. (2023) · Glia · doi:10.1002/glia.24489 · Cited by 13

Authors: García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J.
Affiliations: Neurosciences Institute, University Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
Consejo Superior de Investigaciones Científicas (ES)
Corresponding author: Manzanares, Jorge
ORCID: Navarrete, Francisco
Gasparyan, Ani
Manzanares, Jorge
Venue: Biomolecules
Publisher: MDPI AG
Published: 2020-11-19
Volume: 10
Issue: 11
Pages: 1575
ISSN: 2218-273X (ISSN-L)
DOI: 10.3390/biom10111575
PMC: PMC7699613
OpenAlex: W3101299715
Cited by: 306
References: 213
Citations by year: 2026: 24 · 2025: 79 · 2024: 62 · 2023: 66 · 2022: 46 · 2021: 29
FWCI: 4.62
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Biomolecules (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords: cannabidiol, anxiety, depression, psychosis, anxiolytic effects, antidepressant effects, antipsychotic effects, tetrahydrocannabinol, phytocannabinoids, cannabinoid receptors, CB1 receptor, CB2 receptor, 5-HT1A receptor, neurogenesis, dose-dependent effects, route of administration, clinical trials, risk-benefit profile
MeSH terms: Animals, Anxiety, Cannabidiol, Depression, Dose-Response Relationship, Drug, Drug Administration Routes, Humans, Psychotic Disorders, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks